Influenza immunisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Influenza immunisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Influenza Vaccine Effects on Immune Response in the Nose and Airways in Adults Seeking Protection Against Seasonal Flu https://clinicaltrials.eu/trial/study-of-influenza-vaccine-effects-on-immune-response-in-the-nose-and-airways-in-adults-seeking-protection-against-seasonal-flu/ Wed, 29 Apr 2026 15:08:21 +0000 https://clinicaltrials.eu/trial/study-of-influenza-vaccine-effects-on-immune-response-in-the-nose-and-airways-in-adults-seeking-protection-against-seasonal-flu/ This study examines the effects of influenza vaccination on immune responses in adults who plan to receive their seasonal flu shot. The vaccines being studied include Flucelvax, VAXIGRIPTETRA, and INFLUVAC TETRA, which are all approved vaccines designed to protect against seasonal influenza virus strains. These vaccines contain inactivated or surface parts of different influenza virus strains and are given as a single injection into the muscle. The immune system is the body’s natural defense against infections, and this research focuses on understanding how vaccination affects specific immune cells called memory lymphocytes, which are white blood cells that help the body remember and fight off infections it has encountered before.

The purpose of this study is to examine how flu vaccination impacts two types of immune responses: resident memory immune cells found in the nasal lining and peripheral memory immune cells in the blood that can travel to the respiratory system, which includes the nose, throat, and lungs. Researchers want to understand whether getting a flu vaccine in the arm affects the immune defenses located directly in the nose and airways, where flu viruses typically enter the body. This information could help scientists better understand how flu vaccines work and potentially improve future vaccine strategies.

Participants in this study will receive one of the approved seasonal flu vaccines as they normally would during flu season. Before and after receiving the vaccine, researchers will collect samples from the nose and blood to measure changes in immune cell populations and markers that indicate how these cells move to different parts of the body. The study will also look at antibody levels, which are proteins that help neutralize viruses, and examine gene activity related to immune responses. The research is expected to begin enrolling participants in October 2025 and continue until April 2026.

]]> Study of H5N8 Influenza Vaccine Response in Adults Previously Vaccinated with H5N1 Vaccine Compared to Those Never Vaccinated Against H5 Influenza https://clinicaltrials.eu/trial/study-of-h5n8-influenza-vaccine-immune-response-in-adults-previously-vaccinated-with-h5n1-vaccine-and-in-adults-who-have-never-received-h5-vaccines/ Wed, 29 Apr 2026 15:06:21 +0000 https://clinicaltrials.eu/trial/study-of-h5n8-influenza-vaccine-immune-response-in-adults-previously-vaccinated-with-h5n1-vaccine-and-in-adults-who-have-never-received-h5-vaccines/ This study focuses on testing a vaccine against zoonotic influenza, specifically the H5N8 strain of the virus. The vaccine being tested is a suspension that is injected into the muscle and contains inactivated virus particles combined with an adjuvant called MF59, which helps strengthen the immune response.

The purpose of the study is to examine how well the vaccine works in two different groups of people: those who previously received a different flu vaccine (H5N1) in 2009, and those who have never received this type of vaccine before. The vaccine will be given as two doses over a period of about two months.

During the study, participants will receive injections of the vaccine and have blood samples taken to measure their body’s immune response to the vaccine. The blood tests will check for protective substances called antibodies that the body produces to fight against both the specific virus strain in the vaccine and other similar strains of the flu virus. The total duration of participation in the study will be approximately two months, with several visits to the clinic for vaccinations and blood sampling.

]]> Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-high-dose-influenza-vaccine-in-adults-aged-60-and-over-comparing-trivalent-influenza-vaccine-with-a-drug-combination/ Wed, 29 Apr 2026 15:05:57 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-high-dose-influenza-vaccine-in-adults-aged-60-and-over-comparing-trivalent-influenza-vaccine-with-a-drug-combination/ This clinical trial is focused on studying the effectiveness and safety of a new high-dose vaccine for influenza, commonly known as the flu, in adults aged 60 and older. The study will compare Abbott’s candidate high-dose vaccine, known as Trivalent Influenza Vaccine – High Dose (TIV-HD), with an existing vaccine called Efluelda. Both vaccines are designed to protect against three different strains of the influenza virus, which are updated regularly to match the most common strains circulating each flu season.

The purpose of the study is to determine if the new high-dose vaccine is at least as effective as the existing vaccine in producing an immune response. Participants will receive either the new vaccine or the existing one through an injection. The study will monitor the immune response by measuring specific antibodies in the blood 28 days after vaccination. Participants will also be observed for any side effects or adverse reactions following the vaccination.

The study will take place over several months, with participants being followed up to six months after receiving the vaccine. This will help researchers gather comprehensive data on the vaccine’s safety and its ability to trigger a strong immune response. The ultimate goal is to ensure that the new high-dose vaccine provides effective protection against influenza in older adults, who are at higher risk for complications from the flu.

]]> Study on Antibody Responses in Healthy Individuals After Intranasal and Intramuscular Influenza Vaccination with Fluenz Tetra and Vaxigrip Tetra https://clinicaltrials.eu/trial/study-on-antibody-responses-in-healthy-individuals-after-intranasal-and-intramuscular-influenza-vaccination-with-fluenz-tetra-and-vaxigrip-tetra/ Wed, 29 Apr 2026 15:05:29 +0000 https://clinicaltrials.eu/trial/study-on-antibody-responses-in-healthy-individuals-after-intranasal-and-intramuscular-influenza-vaccination-with-fluenz-tetra-and-vaxigrip-tetra/ This clinical trial is focused on understanding how the body responds to different types of flu vaccines. The study involves two types of influenza vaccines: Fluenz Tetra, which is a nasal spray, and Vaxigrip Tetra, which is given as an injection. Both vaccines are designed to protect against the flu, a common viral infection that affects the respiratory system.

The purpose of the study is to compare the immune response, specifically the production of antibodies, between the two methods of vaccination. Antibodies are proteins made by the immune system to help fight infections. The study will look at how these antibodies develop in the nose and blood after receiving either the nasal spray or the injection. Participants will receive one of the vaccines and will have samples taken from their nose and blood at various times to measure the levels and types of antibodies produced.

The study will take place over several weeks, with participants being monitored at different intervals to track changes in their immune response. This includes measuring specific proteins and cells in the body that are involved in fighting infections. The goal is to better understand how each vaccine works and to gather information that could help improve flu vaccination strategies in the future.

]]> Study on the Effectiveness and Safety of OVX836 Vaccine for Preventing Influenza in Healthy Adults Aged 18-59 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ovx836-vaccine-for-preventing-influenza-in-healthy-adults-aged-18-59/ Wed, 29 Apr 2026 15:05:17 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ovx836-vaccine-for-preventing-influenza-in-healthy-adults-aged-18-59/ This clinical trial is focused on studying the effectiveness and safety of a new influenza vaccine called OVX836. The study is aimed at preventing Influenza Type A, a common viral infection that affects the respiratory system, causing symptoms like fever, cough, and body aches. The vaccine, OVX836, is being tested to see how well it works in preventing the flu compared to a placebo. The trial involves healthy adults aged 18 to 59 years.

Participants in the study will receive a single dose of the OVX836 vaccine through an injection. The study will monitor the occurrence of flu symptoms and any side effects after vaccination. The goal is to determine if the vaccine can effectively prevent the flu and to assess its safety. The study will also look at the body’s immune response to the vaccine, which involves measuring specific immune cells and antibodies that help fight the flu virus.

The trial will take place over a period of time, with participants being observed for any flu symptoms or side effects. The study will also evaluate the severity and duration of any flu-like symptoms that occur. By comparing the results between those who receive the OVX836 vaccine and those who receive a placebo, researchers aim to gather important information about the vaccine’s potential to protect against the flu.

]]> Study on Immune Responses to Influenza Vaccines in Health Care Workers Using Polysorbate 80, Sodium Citrate, and Citric Acid Anhydrous https://clinicaltrials.eu/trial/study-on-immune-responses-to-influenza-vaccines-in-health-care-workers-using-polysorbate-80-sodium-citrate-and-citric-acid-anhydrous/ Wed, 29 Apr 2026 15:05:15 +0000 https://clinicaltrials.eu/trial/study-on-immune-responses-to-influenza-vaccines-in-health-care-workers-using-polysorbate-80-sodium-citrate-and-citric-acid-anhydrous/ This clinical trial is focused on studying the immune responses to influenza vaccinations and viruses among healthcare personnel. Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. The study will use a vaccine that contains inactivated, split virus or surface antigen components, which include strains like A/Texas/50/2012 (H3N2) and A/California/7/2009 (H1N1). These components are designed to help the body build immunity against the flu.

The purpose of the study is to assess the presence and level of antibodies, which are proteins in the blood that fight infections, against the circulating influenza virus strains and the vaccine strains of the current season. Participants will receive the vaccine through an injection into the muscle. Blood samples will be taken before and after vaccination to measure the immune response. The study will also look at cellular immunity, which involves the body’s cells responding to the virus, and will measure substances like cytokines, which are proteins that help control the immune response.

The study will take place over several years, with the goal of understanding how well the vaccine works in healthcare workers who are regularly exposed to the flu. This information could help improve future flu vaccines and protect people from getting sick. Participants will be monitored throughout the study to ensure their safety and to gather important data on how their bodies respond to the vaccine.

]]>